Chemotherapy combined with PD-L1 immunotherapy has become the new standard first-line treatment regimen for extensive stage SCLC by the Food and Drug Administration, due to its substantial survival gains [5–10, 31]. The gene discussed is CD274; the disease is small cell lung carcinoma.